Nephros Inc. Reports 33% Revenue Growth to $18.8 Million for Fiscal Year 2025

Nephros Inc. reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with total net revenues reaching $18.8 million, a 33% increase from $14.2 million in 2024. This growth was primarily driven by higher programmatic revenue, which reflects strong reorder activity and the addition of new active sites, alongside growth in the emergency response business. The company achieved a gross margin of 62%, consistent with the previous year, although margins were impacted in the latter half of the year due to tariffs. Nephros reported a net income of $1.2 million, compared to $74,000 in the prior year, marking a substantial improvement in profitability.

In terms of operational developments, Nephros has focused on expanding its product offerings and market reach. The company launched a new solution validated for the reduction of Total PFAS, enhancing its portfolio to address emerging waterborne contaminants. Nephros continues to serve various sectors, including healthcare, food service, and hospitality, with its medical-grade filters being FDA 510(k)-cleared as Class II medical devices. The company has also seen an increase in its customer base, with major customers accounting for 44% of total revenues in 2025, up from 36% in 2024.

The company’s workforce has remained stable, with 36 full-time employees as of December 31, 2025. Nephros has emphasized the importance of maintaining good employee relations and has experienced limited voluntary turnover. The company’s strategic focus includes leveraging value-added resellers (VARs) to expand its market presence, particularly in the healthcare sector, while also exploring opportunities in commercial markets.

Looking ahead, Nephros anticipates continued growth driven by the increasing demand for its water filtration solutions, particularly in light of heightened regulatory scrutiny on water quality in healthcare settings. However, the company acknowledges potential challenges, including market acceptance of its products and the impact of tariffs on gross margins. Nephros has expressed confidence in its ability to sustain profitability and manage operating costs effectively, although it remains cautious about future revenue growth and the need for additional capital to support its operations. The company is committed to enhancing its internal controls and addressing previously identified weaknesses in its financial reporting processes.